AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20421333 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 18775846 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen therapy (ET; 1 mg/day for 6 months)
Number of subjects: 18
Study 18775846 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=9)
Number of subjects: 18
Study 15677607 — intervention group
Group type: EXPERIMENTAL
Intervention: ondansetron (16 mg)
Number of subjects: 8
Study 15677607 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 8
Study 11802285 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational program (workshop including crisis management, use of inhaled medication, flow‐metry, and relaxation techniques)
Number of subjects: 76
Study 11802285 — intervention group
Group type: COMPARATOR
Intervention: Control group (no educational program)
Number of subjects: 76
Study 9751674 — intervention group
Group type: EXPERIMENTAL
Intervention: Xemilofiban 20 mg
Number of subjects: 549
Study 9751674 — intervention group
Group type: EXPERIMENTAL
Intervention: Xemilofiban 15 mg
Number of subjects: 549
Study 9751674 — intervention group
Group type: COMPARATOR
Intervention: Placebo with ticlopidine 250 mg
Number of subjects: 549
Study 7849747 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-tech exercise
Number of subjects: 250
Study 7849747 — intervention group
Group type: EXPERIMENTAL
Intervention: High-tech exercise
Number of subjects: 250
Study 7849747 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 250
Study 2904751 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin monotherapy
Number of subjects: 24
Study 2904751 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin combined with beta-blocker
Number of subjects: 24
Study 2904751 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall doxazosin therapy
Number of subjects: 24
Study 2904751 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin therapy
Number of subjects: 24
Study 31714444 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological intervention during different stages of the operation
Number of subjects: 100
Study 31714444 — intervention group
Group type: COMPARATOR
Intervention: Routine nursing care
Number of subjects: 100
Study 30419956 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyadic planning intervention
Number of subjects: 0
Study 30419956 — intervention group
Group type: COMPARATOR
Intervention: Individual planning condition
Number of subjects: 0
Study 26553313 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram 20 mg/day for 52 weeks
Number of subjects: 74
Study 26553313 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 52 weeks
Number of subjects: 74
Study 24853083 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline Q-wave width ≥40ms for inferior MI
Number of subjects: 3589
Study 24853083 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline Q-wave width ≥20ms for lateral/apical MI
Number of subjects: 3589
Study 24853083 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline Q-wave width
Number of subjects: 3589
Study 22071380 — intervention group
Group type: EXPERIMENTAL
Intervention: VDD pacing (n=166)
Number of subjects: 420
Study 22071380 — intervention group
Group type: COMPARATOR
Intervention: DDD pacing (n=254)
Number of subjects: 420
Study 22071380 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 420
Study 20456062 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric bupivacaine plus 0.2 microg.kg(‐1) of fentanyl
Number of subjects: 50
Study 20456062 — intervention group
Group type: COMPARATOR
Intervention: Hyperbaric bupivacaine plus 0.9% NaCl (placebo)
Number of subjects: 50
Study 17988903 — intervention group
Group type: EXPERIMENTAL
Intervention: Interobserver agreement on presence of rupture
Number of subjects: 51
Study 17988903 — intervention group
Group type: EXPERIMENTAL
Intervention: Interobserver agreement on suitability for EVAR
Number of subjects: 51
Study 17988903 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraobserver agreement on presence of rupture
Number of subjects: 51
Study 17988903 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraobserver agreement on suitability for EVAR
Number of subjects: 51
Study 17988903 — intervention group
Group type: EXPERIMENTAL
Intervention: Diameter and length of the infrarenal aortic neck
Number of subjects: 51
Study 17988903 — intervention group
Group type: EXPERIMENTAL
Intervention: Diameters of left iliac artery
Number of subjects: 51
Study 17988903 — intervention group
Group type: EXPERIMENTAL
Intervention: Diameters of right iliac artery
Number of subjects: 51
Study 15995092 — intervention group
Group type: EXPERIMENTAL
Intervention: Six‐Item Screener (SIS)
Number of subjects: 149
Study 15995092 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini‐Cog
Number of subjects: 149
Study 15995092 — intervention group
Group type: COMPARATOR
Intervention: Mini‐Mental State Examination (MMSE)
Number of subjects: 149
Study 12360157 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss intervention
Number of subjects: 86
Study 9855830 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.04 tapered nickel‐titanium (NiTi) rotary instrumentation
Number of subjects: 48
Study 9855830 — intervention group
Group type: COMPARATOR
Intervention: Stainless‐steel K‐file step‐back technique
Number of subjects: 48
Study 7534239 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (100 micrograms) administered subcutaneously
Number of subjects: 17
Study 2552487 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoproterenol
Number of subjects: 12
Study 2552487 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 12
Study 2552487 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 2552487 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral challenge (mental arithmetic)
Number of subjects: 12
Study 2552487 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral challenge (structured interview)
Number of subjects: 12
Study 931586 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual scanning training program
Number of subjects: 57
Study 931586 — intervention group
Group type: COMPARATOR
Intervention: Standard rehabilitation (Control)
Number of subjects: 57
Study 31768000 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher educational attainment (1 additional year)
Number of subjects: 334507
Study 30392424 — intervention group
Group type: EXPERIMENTAL
Intervention: MCT/LCT-based PN containing ω‐3 fish‐oil emulsion
Number of subjects: 174
Study 30392424 — intervention group
Group type: COMPARATOR
Intervention: Control group (MCT/LCT-based PN)
Number of subjects: 174
Study 30100299 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio taping applied directly above the MTrPs in the active intervention group.
Number of subjects: 30
Study 30100299 — intervention group
Group type: COMPARATOR
Intervention: Control group with kinesio taping applied a few centimeters away from the MTrPs.
Number of subjects: 30
Study 30100299 — intervention group
Group type: COMPARATOR
Intervention: Comparison of PPT measurements between the active intervention group and controls.
Number of subjects: 30
Study 27471804 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% NaF varnish (F), two applications with one-week interval
Number of subjects: 35
Study 27471804 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine gel (CHX), two applications with one-week interval
Number of subjects: 35
Study 27471804 — intervention group
Group type: COMPARATOR
Intervention: Usual home care (CO)
Number of subjects: 35
Study 24563017 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 116
Study 24563017 — intervention group
Group type: COMPARATOR
Intervention: NPH insulin
Number of subjects: 116
Study 20163365 — intervention group
Group type: EXPERIMENTAL
Intervention: Micro-coaxial phacoemulsification
Number of subjects: 89
Study 20163365 — intervention group
Group type: COMPARATOR
Intervention: Bimanual phacoemulsification
Number of subjects: 89
Study 20163365 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 89
Study 21162925 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy (for Group A with D-dimer > 512 µg/L)
Number of subjects: 47
Study 21162925 — intervention group
Group type: COMPARATOR
Intervention: No thrombolytic therapy (for Group C)
Number of subjects: 47
Study 21162925 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy (for Group B with D-dimer < 512 µg/L)
Number of subjects: 47
Study 17926468 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (mean dose 21.9 +/- 9.0 mg/day) with adjuvant indapamide (2.5 mg/day)
Number of subjects: 237
Study 17926468 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril with indapamide
Number of subjects: 237
Study 16379495 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 23
Study 16379495 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 23
Study 12549699 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevention trial methods
Number of subjects: 0
Study 12549699 — intervention group
Group type: EXPERIMENTAL
Intervention: Empirical literature on the development and prevention of internalizing disorders, particularly depression
Number of subjects: 0
Study 9952149 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg ondansetron intravenously in 100 ml NaCl 0.9%
Number of subjects: 100
Study 9952149 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (placebo)
Number of subjects: 100
Study 9952149 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg ondansetron intravenously
Number of subjects: 100
Study 7562753 — intervention group
Group type: EXPERIMENTAL
Intervention: Single photon emission computerized tomography (SPECT)
Number of subjects: 14
Study 7562753 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of SPECT and brain scan
Number of subjects: 14
Study 7562753 — intervention group
Group type: EXPERIMENTAL
Intervention: SPECT
Number of subjects: 14
Study 2207773 — intervention group
Group type: EXPERIMENTAL
Intervention: iohexol 240 mg I/ml
Number of subjects: 117
Study 2207773 — intervention group
Group type: EXPERIMENTAL
Intervention: iohexol 300 mg I/ml
Number of subjects: 117
Study 2207773 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical myelography
Number of subjects: 117
Study 2207773 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher concentration of iohexol (300 mg I/ml)
Number of subjects: 117
Study 2207773 — intervention group
Group type: COMPARATOR
Intervention: Lower concentration of iohexol (240 mg I/ml)
Number of subjects: 117
Study 2207773 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall side-effects
Number of subjects: 117
Study 394624 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentazocine 30 mg
Number of subjects: 49
Study 394624 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentazocine 15 mg
Number of subjects: 49
Study 394624 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 31130655 — intervention group
Group type: EXPERIMENTAL
Intervention: Altered viruses with at least 11 different amino acid substitutions in the tripeptide of 3CD.
Number of subjects: 51
Study 31130655 — intervention group
Group type: EXPERIMENTAL
Intervention: Debilitated (but viable) genomes.
Number of subjects: 51
Study 31130655 — intervention group
Group type: EXPERIMENTAL
Intervention: Mutational tolerance of oriL.
Number of subjects: 51
Study 28658163 — intervention group
Group type: EXPERIMENTAL
Intervention: Electro-acupuncture (group EA) applied on Baihui, Dazhui, and Zusanli acupoints 30 minutes before anesthesia.
Number of subjects: 90
Study 28658163 — intervention group
Group type: EXPERIMENTAL
Intervention: Electro-acupuncture (group EA)
Number of subjects: 90
Study 28658163 — intervention group
Group type: COMPARATOR
Intervention: Control group (group C)
Number of subjects: 90
Study 25559906 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance before aerobic training (RA)
Number of subjects: 26
Study 25559906 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance after aerobic training (AR)
Number of subjects: 26
Study 24433682 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic testing for colorectal cancer
Number of subjects: 3469
Study 24433682 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic testing for lung cancer
Number of subjects: 3469
Study 24433682 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic testing for pancreatic cancer
Number of subjects: 3469
Study 24433682 — intervention group
Group type: EXPERIMENTAL
Intervention: General preference for diagnostic testing
Number of subjects: 3469
Study 22947547 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training
Number of subjects: 57
Study 22947547 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined aerobic-resistance training
Number of subjects: 57
Study 22947547 — intervention group
Group type: EXPERIMENTAL
Intervention: Impact exercises
Number of subjects: 57
Study 22947547 — intervention group
Group type: COMPARATOR
Intervention: Sedentary control
Number of subjects: 57
Study 22947547 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 57
Study 18534496 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose continuous FNB
Number of subjects: 60
Study 18534496 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose continuous FNB
Number of subjects: 60
Study 18534496 — intervention group
Group type: COMPARATOR
Intervention: No FNB
Number of subjects: 60
Study 17500613 — intervention group
Group type: EXPERIMENTAL
Intervention: Experiential smoking intervention
Number of subjects: 0
Study 17500613 — intervention group
Group type: COMPARATOR
Intervention: Traditional didactic smoking intervention
Number of subjects: 0
Study 17500613 — intervention group
Group type: COMPARATOR
Intervention: Experiential intervention on nutrition
Number of subjects: 0
Study 15342302 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg/day
Number of subjects: 40
Study 15342302 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 11150622 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-training patients (n=17)
Number of subjects: 54
Study 11150622 — intervention group
Group type: COMPARATOR
Intervention: Controls (n=20)
Number of subjects: 54
Study 9640633 — intervention group
Group type: EXPERIMENTAL
Intervention: Two session standardized intervention
Number of subjects: 1403
Study 1339011 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatinum 20 mg/m2/day + Etoposide 60 mg/m2/day (arm A)
Number of subjects: 37
Study 1339011 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatinum 40 mg/m2/day + Etoposide 100 mg/m2/day (arm B)
Number of subjects: 37
Study 1339011 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 37
Study 3559150 — intervention group
Group type: EXPERIMENTAL
Intervention: PK 8165 (pipequaline) 50 mg
Number of subjects: 12
Study 3559150 — intervention group
Group type: EXPERIMENTAL
Intervention: PK 8165 (pipequaline) 150 mg
Number of subjects: 12
Study 3559150 — intervention group
Group type: COMPARATOR
Intervention: Diazepam 10 mg
Number of subjects: 12
Study 3559150 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31364992 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-fit, air-cell mattress
Number of subjects: 52
Study 31364992 — intervention group
Group type: COMPARATOR
Intervention: 2-layer air mattress (Control)
Number of subjects: 52
Study 29877609 — intervention group
Group type: EXPERIMENTAL
Intervention: Simpler care (SC)
Number of subjects: 124
Study 26708696 — intervention group
Group type: EXPERIMENTAL
Intervention: CI3D (three-dimensional echocardiography)
Number of subjects: 45
Study 26708696 — intervention group
Group type: EXPERIMENTAL
Intervention: CI2D (two-dimensional echocardiography)
Number of subjects: 45
Study 26708696 — intervention group
Group type: EXPERIMENTAL
Intervention: CIFT (FloTrac/Vigileo)
Number of subjects: 45
Study 24679633 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab with bevacizumab (10 mg/kg I.V. on days 3 and 15)
Number of subjects: 60
Study 24679633 — intervention group
Group type: COMPARATOR
Intervention: Rituximab alone (375 mg/m(2) I.V. weekly for 4 weeks)
Number of subjects: 60
Study 24679633 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab with bevacizumab
Number of subjects: 60
Study 24679633 — intervention group
Group type: COMPARATOR
Intervention: Rituximab alone
Number of subjects: 60
Study 21334155 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonographic sliding lung sign (SLS) detection after brief tutorial
Number of subjects: 8
Study 21334155 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonographic sliding lung sign (SLS) detection after 9-month follow-up
Number of subjects: 8
Study 20643730 — intervention group
Group type: EXPERIMENTAL
Intervention: Real cupping therapy
Number of subjects: 34
Study 20643730 — intervention group
Group type: COMPARATOR
Intervention: Sham cupping
Number of subjects: 34
Study 20643730 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (real and sham cupping)
Number of subjects: 34
Study 17397525 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive pacing therapy
Number of subjects: 600
Study 17397525 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy
Number of subjects: 600
Study 17397525 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded exercise therapy
Number of subjects: 600
Study 17397525 — intervention group
Group type: COMPARATOR
Intervention: Standardised specialist medical care
Number of subjects: 600
Study 16192516 — intervention group
Group type: EXPERIMENTAL
Intervention: PPI (rabeprazol 20 mg)
Number of subjects: 48
Study 16192516 — intervention group
Group type: COMPARATOR
Intervention: H2 group (roxatidine 75 mg)
Number of subjects: 48
Study 12523578 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral valacyclovir (VAL), 1 g orally every 12 hours from day 0 to engraftment
Number of subjects: 30
Study 12523578 — intervention group
Group type: COMPARATOR
Intervention: Intravenous acyclovir (ACY), 250 mg/m2 intravenously every 12 hours from day 0 to engraftment
Number of subjects: 30
Study 9819549 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive ANA test (n = 43)
Number of subjects: 121
Study 8547959 — intervention group
Group type: EXPERIMENTAL
Intervention: Roferon-A 1 million units subcutaneously daily
Number of subjects: 56
Study 2335174 — intervention group
Group type: COMPARATOR
Intervention: Hypoxia (10.8 +/- 0.6% oxygen) during 45 s Wingate test
Number of subjects: 12
Study 2335174 — intervention group
Group type: COMPARATOR
Intervention: Hypoxia (10.8 +/- 0.6% oxygen) during 30 s Wingate test
Number of subjects: 12
Study 6262206 — intervention group
Group type: EXPERIMENTAL
Intervention: FK 33-824, 0.5 mg i.m.
Number of subjects: 14
Study 6262206 — intervention group
Group type: COMPARATOR
Intervention: Naloxone, 4 mg i.v.
Number of subjects: 14
Study 6262206 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 31537574 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart‐ROCQ programme (multidisciplinary cardiac rehabilitation)
Number of subjects: 350
Study 31537574 — intervention group
Group type: COMPARATOR
Intervention: Standard care (6 weeks of postsurgery outpatient CR)
Number of subjects: 350
Study 28945145 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP+diode laser
Number of subjects: 31
Study 28945145 — intervention group
Group type: COMPARATOR
Intervention: SRP alone
Number of subjects: 31
Study 25682778 — intervention group
Group type: EXPERIMENTAL
Intervention: Client strategy (written information leaflets and decision aid)
Number of subjects: 1613
Study 25682778 — intervention group
Group type: EXPERIMENTAL
Intervention: Care-provider strategy (1-day counseling course focused on knowledge and counseling skills)
Number of subjects: 1613
Study 25682778 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined client and care-provider strategy
Number of subjects: 1613
Study 25682778 — intervention group
Group type: COMPARATOR
Intervention: Care-as-usual strategy
Number of subjects: 1613
Study 25682778 — intervention group
Group type: EXPERIMENTAL
Intervention: Women actually offered intervention (client strategy)
Number of subjects: 1613
Study 25682778 — intervention group
Group type: EXPERIMENTAL
Intervention: Women actually offered intervention (care-provider strategy)
Number of subjects: 1613
Study 24284606 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual feedback posturography training
Number of subjects: 25
Study 24284606 — intervention group
Group type: EXPERIMENTAL
Intervention: Vestibular rehabilitation
Number of subjects: 25
Study 24284606 — intervention group
Group type: COMPARATOR
Intervention: Home exercise group
Number of subjects: 25
Study 21314751 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with zero to one drug users in their social networks
Number of subjects: 57
Study 21314751 — intervention group
Group type: COMPARATOR
Intervention: Patients with ≥ 2 drug users in their social networks
Number of subjects: 57
Study 21314751 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who consistently named multiple drug users in their social networks
Number of subjects: 57
Study 21314751 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who never or occasionally named multiple drug users
Number of subjects: 57
Study 19166565 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium registry utilization
Number of subjects: 661
Study 19166565 — intervention group
Group type: EXPERIMENTAL
Intervention: High registry utilization
Number of subjects: 661
Study 19166565 — intervention group
Group type: COMPARATOR
Intervention: Low registry utilization
Number of subjects: 661
Study 16732086 — intervention group
Group type: EXPERIMENTAL
Intervention: LMA‐Unique (LMA‐U)
Number of subjects: 320
Study 16732086 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft Seal laryngeal mask (SS‐LM)
Number of subjects: 320
Study 16732086 — intervention group
Group type: COMPARATOR
Intervention: Cobra perilaryngeal airway (Cobra‐PLA)
Number of subjects: 320
Study 15605688 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil/Pharmathen (test preparation)
Number of subjects: 24
Study 11223309 — intervention group
Group type: EXPERIMENTAL
Intervention: Edmonton Labeled Visual Information System (ELVIS)
Number of subjects: 16
Study 11223309 — intervention group
Group type: COMPARATOR
Intervention: Text cases
Number of subjects: 16
Study 9143547 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger group
Number of subjects: 49
Study 9143547 — intervention group
Group type: COMPARATOR
Intervention: Elderly group
Number of subjects: 49